Program Highlights
- Game-changing liquid biopsy assays for early cancer diagnostics
- Applications of gene editing in target identification and drug screening
- Development of cutting-edge gene therapies using CRISPR technology
- Liquid biopsy in drug development and patient care
- Showcase of success stories of artificial intelligence in disease diagnostics
- Applications of artificial intelligence in addressing unmet medical needs
Program Agenda
8:20 – 8:45 Registration and Network
8:45 – 8:50 Welcome, Stephanie Shi, Ph.D., President of SABPA
8:50 – 9:00 FTD Opening Remarks, Hua Gong, MD, Ph.D., Chair FTD committee
Morning Session Chair, Hua Gong, MD, Ph.D., Chair of FTD committee
9:00 – 9:30 Keynote Presentation, Alex Aravanis, MD, Ph.D., Head of R&D, Grail, “Development of Early Cancer Detection Tests Based on Sequencing of Cell-Free Nucleic Acids“.
9:30 – 10:00 Presentation, Helmy Eltoukhy, Ph.D., CEO, Guardant health, “From Wired to Wireless: Current progress and future directions of liquid biopsies in oncology“.
10:00 – 10:30 Presentation, Wendy Winckler, Ph.D., Executive Director, Novartis, “Biomarkers of Response and Resistance in the Circulation“.
10:30 – 11:00 Coffee Break
11:00 – 12:10 Panel Discussion, “Liquid biopsy new development in Oncology diagnostics“. Moderator: Hatim Husain, MD.
- Lyle Arnold, Ph.D., CSO, Biocept
- Dongliang Ge, Ph.D., CEO, Apostle Inc
- Hatim Husain, MD, Assistant Professor of Medicine, Moores Cancer Center, UCSD
- Shidong Jia, Ph.D., CEO, PREDICINE
- Traci Pawlowski, Ph.D., Senior Director Product Development, Oncology at Illumina
12:00 – 1:30 Lunch Break
Afternoon Session Chair, Howard Pan, Ph.D., Co-Chair of FTD committee
1:30 – 2:00 Presentation, Xiaohui Xie, Ph.D., Professor, UC Irvine, “Deep Learning in Genomics and Medicine”
2:00 – 2:30 Keynote Presentation, Michael White, Ph.D., VP, CSO, Pfizer Oncology R&D, “Harnessing cancer genome diversity for intervention target discovery“.
2:30 – 3:00 Presentation, Tony Ho, Ph.D., Head of Research and Development, CRISPR Therapeutics, “Bring CRISPR to the Clinic“.
3:00 – 3:30 Coffee Break
3:30 – 4:55 Panel Discussion, “Application of Novel Gene Editing Technologies in Drug Discovery and Development“. Moderator: Lawrence Lum, Ph.D.
- Patrick D. Hsu, Ph.D., Principal Investigator, Salk Institute
- Alexis C. Komor, Ph.D., Assistant Professor, Department of Chemistry and Biochemistry, UCSD
- Lawrence Lum, Ph.D., Director, Cancer Systems Therapeutics, Pfizer Oncology R&D
- Prashant Mali, Ph.D., Assistant Professor, Synthetic Biology, UCSD
- Prasun Mishra, Ph.D., CEO, Agility Pharmaceuticals
- Marco Weinberg, Ph.D., Research fellow, Vertex Pharmaceuticals
4:55 – 5:00 Closing Remarks, Peter Huang, Ph.D. EVP, SABPA
5:00 – 6:00 Cocktail Hours